<p>The ligand (BHMDMA) (E)-4-((2-(benzo_[d]oxazol-2-yl)hydrazineylidenes)methyl)-N, N-dimethylaniline reacted with Zn (II) chloride dissolved in ethanol to form the zinc (II) complex. Two processes were taken to prepare the novel ligand (BHMDMA). The first step was to make the compound (A) 2-hydrazinylbenzooxazole by reacting 2-Mercaptobenzoxazole in ethanol with Hydrazine hydrate. The reaction of compound A with 4-dimethylaminobenzaldehyde was the second step in the preparation of the ligand (BHMDMA). The structures of the ligand (BHMDMA) and the Zn (II) complex were confirmed by ¹H-¹³C-NMR, UV-Vis spectra; FT-IR, elemental analyses (CHN); molar conductivity; atomic absorption; melting points and magnetic susceptibility measurements; In contrast, a 1:1 (M: L) ratio was used to create the Zn(II) complex. It appears to have a tetrahedral geometry. It was shown that the ligand (BHMDMA) and its complex have significant biological activity against a variety of bacterial species. The synthesized compounds were theoretically studied through their molecular docking and binding to the protein (3O2F). They were then applied practically through toxicity studies on two types of breast cancer cells (MCF-7) and live WRL68 cells. Significant changes in IC₅₀ values were observed between infected and healthy cells. In addition, the antioxidant and antifibrinolytic properties shown below were studied.</p> Graphical abstract <p></p>